MS1 VALIDATION OF MODELED 5-YEAR SURVIVAL OUTCOMES AMONG PATIENTS WITH CYSTIC FIBROSIS (CF) TREATED WITH THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATOR (CFTRM) IVACAFTOR USING US CF FOUNDATION PATIENT REGISTRY (USCFFPR) DATA

Autor:	Mcgarry, L., Lopez, A., Chandler, C., Pelligra, C., Alkhateeb, Z., Rubin, J.L., Liou, T.
Zdroj:	In Value in Health May 2020 23 Supplement 1:S8-S8
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect